Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Demyelination and Remyelination: From Mechanism to Therapy
American Society for Neurochemistry 47th Annual Meeting
MS Patient, Ph.D.: Can We Separate Anxiety and Gender in MS?
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis.
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
Episode 48 with Dr. Bruce Cree on the EPIC, CLIMB, and SUMMIT clinical studies
MS Research Roundup: May 16, 2014
The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease.
Episode 55 with Dr. Michael Levy on the status of regenerative stem cell therapies for multiple sclerosis
The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
MS Research Roundup: July 18, 2014
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
Gender-specific expression of beta1 integrin of VLA-4 in myelin basic protein-primed T cells: implications for gender bias in multiple sclerosis.
Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
ACTRIMS-ECTRIMS 2014 -- Day 3, afternoon
Viral triggers of multiple sclerosis.
Fcγ receptors in Norwegian multiple sclerosis patients and healthy controls.
FP187 – Oral Immunomodulatory Dimethyl Fumarate (DMF)
Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study.
Gender as risk factor for autoimmune diseases.
Episode 44 with Dr. Monika Bradl on an animal model for neuromyelitis optica (NMO)
Episode 37 with Dr. Jeanne Loring on human pluripotent stem cells in a mouse model of MS
Pages
« first
‹ previous
…
45
46
47
48
49
50
51
52
53
…
next ›
last »